Drug Therapy for Infectious Diseases of the Dog and Cat (eBook)

Valerie J. Wiebe (Autor)

eBook Download: PDF

2015
John Wiley & Sons (Verlag)
9781118557471 (ISBN)

Infos

Drug Therapy for Infectious Diseases of the Dog and Cat provides fast access to all the information needed to effectively and responsibly treat infectious disease in dogs and cats, with easy searching by either drug or organism.

• Provides fast access to essential information on prescribing antibiotics, antifungals, antiparasitics, and antivirals
• Offers alphabetical searching by either drug or organism
• Focuses on clinically relevant information
• Covers information on each drug using a common format for ease of use
• Presents a reliable quick reference to the correct use of antibiotics in veterinary practice

Valerie J. Wiebe, Pharm. D, FSVHP, Dip. ICVP, is the Director of Pharmacy at the University of California, Davis Veterinary Medical Teaching Hospital, where she has an appointment as Adjunct Associate Professor in the Department of Internal Medicine, in Davis, California, USA. She also maintains an adjunct Clinical Professorship at the University of San Francisco, Department of Pharmacy, in San Francisco, California, USA.

Inhalt

Title Page 5
Copyright Page 6
Contents 7
Preface 11
Acknowledgments 12
Section A Pharmacology Guidelines 13
Chapter 1: Understanding Minimum Inhibitory Concentrations (MICs) 13
Chapter 2: Static versus Cidal Antibiotics 13
Bacteriostatic 13
Bactericidal 14
Chapter 3: In Vitro versus In Vivo Efficacy 14
Chapter 4: Approaching Infectious Disease Cases 14
Is this an infection? 14
Where is the infection? 14
What are the most likely pathogens at this site? 14
Empirically, what will cover these pathogens? 14
What other factors must be considered? 14
What patient factors should be considered? 16
What route of administration should be used? 16
What dose should be used? 16
How long should the animal be treated? 16
When should I perform culture and sensitivity? 16
Chapter 5: Why Antibiotics Fail 16
Chapter 6: Adjusting Doses in Renal Failure 17
Interval adjustment 18
Dose adjustment 18
No dose adjustment 18
Chapter 7: Pregnancy Risk Categories 18
Categories 19
Chapter 8: Lactation Guidelines: Penetration of Drugs into Milk 19
Chapter 9: Safe Writing Skills 19
Chapter 10: Basic Math Skills 20
Dilutions 20
Percent solutions 20
Percent weights 20
Converting units 20
Weight conversions 20
Liquid conversions 20
Milliequivalents 20
Section B Empiric Therapy Pending Diagnostic Results 21
Chapter 11: Arthritis, Osteomyelitis 21
Clinical presentation 21
Likely pathogens 21
Diagnosis 21
Empiric drug therapy 21
Further reading 22
Chapter 12: Bacteremia and Sepsis 22
Clinical presentation 22
Likely pathogens 22
Diagnosis 22
Empiric drug therapy 22
Resistant organisms 22
Further reading 22
Chapter 13: Central Nervous System Infections (Meningitis) 23
Clinical presentation 23
Likely pathogens 23
Diagnosis 23
Empiric drug therapy 23
Further reading 23
Chapter 14: Endocarditis (Bacterial) 24
Clinical presentation 24
Likely pathogens 24
Obtaining blood cultures 24
Empiric drug therapy 24
Further reading 25
Chapter 15: Intra-Abdominal Infections 25
Clinical presentation 25
Likely pathogens 25
Diagnosis 25
Empiric drug therapy 25
Further reading 26
Chapter 16: Neonatal Infections 26
Clinical presentation 26
Likely pathogens 26
Diagnosis 26
Empiric drug therapy 26
Further reading 26
Chapter 17: Infections Associated with Neutropenia 27
Clinical presentation 27
Likely pathogens 27
Diagnosis 27
Empiric drug therapy 27
Further reading 27
Chapter 18: Otitis Externa and Otitis Media 27
Clinical presentation 27
Likely pathogens 28
Diagnosis 28
Empiric drug therapy 28
Further reading 28
Chapter 19: Pancreatitis 28
Clinical presentation 28
Likely pathogens 29
Diagnosis 29
Empiric drug therapy 29
Further reading 29
Chapter 20: Peritonitis and Abscesses 29
Clinical presentation 29
Likely pathogens 29
Diagnosis 29
Treatment 30
Further reading 30
Chapter 21: Pneumonia/Bronchitis 30
Clinical presentation 30
Likely pathogens 30
Diagnosis 30
Empiric drug therapy 30
Further reading 31
Chapter 22: Prostatitis 31
Clinical presentation 31
Likely pathogens 31
Diagnosis 31
Empiric drug therapy 31
Further reading 31
Chapter 23: Pyothorax Infections 32
Clinical presentation 32
Likely pathogens 32
Diagnosis 32
Empiric drug therapy 32
Further reading 32
Chapter 24: Sinus Infections 32
Clinical presentation 32
Likely pathogens 33
Diagnosis 33
Empiric drug therapy 33
Further reading 33
Chapter 25: Skin and Soft Tissue Infections 33
Clinical presentation 33
Likely pathogens 34
Diagnosis 34
Empiric drug therapy 34
Further reading 34
Chapter 26: Urinary Tract Infections 34
Clinical presentation 34
Diagnosis 34
Interpretation of MICs 35
Organisms 35
Empiric treatment 35
Resistant organisms 35
Further reading 35
Section C Therapy of Established Infections 37
Chapter 27: Acanthamoeba 37
Microbiology/epidemiology 37
Clinical disease 37
Diagnosis 37
Treatment 37
Drug therapy 38
Drug therapy alternatives 38
Further reading 38
Chapter 28: Acinetobacter 38
Microbiology/epidemiology 38
Clinical disease 38
Diagnosis 38
Treatment 38
Further reading 39
Chapter 29: Actinomyces 39
Microbiology/epidemiology 39
Clinical disease 39
Diagnosis 39
Treatment 39
Drug therapy 40
Drug therapy alternatives 40
Further reading 40
Chapter 30: Adenovirus (Infectious Canine Hepatitis) 40
Microbiology/epidemiology 40
Clinical disease 40
Diagnosis 40
Treatment 40
Drug therapy 41
Further reading 41
Chapter 31: Aelurostrongylus Abstrusus (Feline Lungworm) 41
Microbiology/epidemiology 41
Clinical disease 41
Diagnosis 41
Treatment 41
Drug therapy 41
Drug therapy alternatives 41
Further reading 41
Chapter 32: Anaerobic Species (Bacteroides and Provotella) 42
Microbiology/epidemiology 42
Clinical disease 42
Diagnosis 42
Treatment 42
Drug therapy 42
Drug therapy alternatives 42
Further reading 42
Chapter 33: Anaplasma Species 42
Microbiology/epidemiology 43
Clinical disease 43
Diagnosis 43
Treatment 43
Drug therapy 43
Drug therapy alternatives 43
Further reading 43
Chapter 34: Ancylostoma Species (Hookworms) 43
Microbiology/epidemiology 43
Clinical disease 44
Diagnosis 44
Treatment 44
Drug therapy 44
Drug therapy alternatives 44
Further reading 44
Chapter 35: Ascaris Species (Roundworms) 44
Microbiology/epidemiology 45
Clinical disease 45
Diagnosis 45
Treatment 45
Drug therapy 45
Drug therapy alternatives 45
Further reading 45
Chapter 36: Aspergillus Species 45
Microbiology/epidemiology 46
Clinical disease 46
Diagnosis 46
Treatment 46
Drug therapy 47
Drug therapy alternatives 47
Further reading 47
Chapter 37: Babesia Species 47
Microbiology/epidemiology 47
Clinical disease 47
Diagnosis 48
Treatment 48
Drug therapy 48
Drug therapy alternatives 48
Further reading 48
Chapter 38: Bartonella Species (Cat Scratch Disease) 48
Microbiology/epidemiology 48
Clinical disease 49
Diagnosis 49
Treatment 49
Drug therapy 49
Drug therapy alternatives 49
Further reading 49
Chapter 39: Blastomycosis 49
Microbiology/epidemiology 49
Clinical disease 50
Diagnosis 50
Treatment 50
Drug therapy 50
Drug therapy alternatives 50
Further reading 50
Chapter 40: Bordetella Bronchiseptica (Kennel Cough) 50
Microbiology/epidemiology 50
Clinical disease 51
Diagnosis 51
Treatment 51
Drug therapy 51
Drug therapy alternatives 51
Further reading 51
Chapter 41: Borrelia Burgdorferi (Lyme Disease) 51
Microbiology/epidemiology 51
Clinical disease 52
Diagnosis 52
Treatment 52
Drug therapy 52
Drug therapy alternatives 52
Further reading 52
Chapter 42: Brucella (Canine Brucellosis) 52
Microbiology/epidemiology 53
Clinical disease 53
Diagnosis 53
Treatment 53
Drug therapy 53
Drug therapy alternatives 53
Further reading 53
Chapter 43: Calicivirus 54
Microbiology/epidemiology 54
Clinical disease 54
Diagnosis 54
Treatment 54
Drug therapy 54
Drug therapy alternatives 54
Further reading 54
Chapter 44: Campylobacter Species 55
Microbiology/epidemiology 55
Clinical disease 55
Diagnosis 55
Treatment 55
Drug therapy 55
Drug therapy alternatives 55
Further reading 55
Chapter 45: Candida Species 55
Microbiology/epidemiology 55
Clinical disease 56
Diagnosis 56
Treatment 56
Drug therapy 56
Drug therapy alternatives 56
Further reading 56
Chapter 46: Canine Influenza Virus (CIV) 56
Microbiology/epidemiology 57
Clinical disease 57
Diagnosis 57
Treatment 57
Drug therapy 57
Further reading 57
Chapter 47: Capillaria Aerophila (Lungworm) 57
Microbiology/epidemiology 58
Clinical disease 58
Diagnosis 58
Treatment 58
Drug therapy 58
Drug therapy alternatives 58
Further reading 58
Chapter 48: Cestode Species (Tapeworms) 58
Microbiology/epidemiology 58
Clinical disease 59
Diagnosis 59
Treatment 59
Drug therapy 59
Drug therapy alternatives 59
Further reading 59
Chapter 49: Cheyletiella Species (Walking Dandruff) 59
Microbiology/epidemiology 59
Clinical disease 60
Diagnosis 60
Treatment 60
Drug therapy 60
Drug therapy alternatives 60
Further reading 60
Chapter 50: Chlamydia Species 60
Microbiology/epidemiology 60
Clinical disease 61
Diagnosis 61
Treatment 61
Drug therapy 61
Drug therapy alternatives 61
Further reading 61
Chapter 51: Citrobacter Species 61
Microbiology/epidemiology 61
Clinical disease 61
Diagnosis 62
Treatment 62
Drug therapy 62
Drug therapy alternatives 62
Further reading 62
Chapter 52: Clostridium Difficile 62
Microbiology/epidemiology 62
Clinical disease 62
Diagnosis 63
Treatment 63
Drug therapy 63
Drug therapy alternatives 63
Further reading 63
Chapter 53: Clostridium Tetani/Botulinum 63
Microbiology/epidemiology 63
Clinical disease 63
Diagnosis 63
Treatment 64
Drug therapy 64
Drug therapy alternatives 64
Further reading 64
Chapter 54: Coccidiomycosis 64
Microbiology/epidemiology 64
Clinical disease 64
Diagnosis 64
Treatment 64
Drug therapy 65
Drug therapy alternatives 65
Further reading 65
Chapter 55: Corynebacterium Species 65
Microbiology/epidemiology 65
Clinical disease 65
Diagnosis 65
Treatment 65
Drug therapy 66
Drug therapy alternatives 66
Further reading 66
Chapter 56: Coxiellosis Species (Q Fever) 66
Microbiology/epidemiology 66
Clinical disease 66
Diagnosis 66
Treatment 66
Drug therapy 66
Drug therapy alternatives 66
Further reading 67
Chapter 57: Cryptococcus Species 67
Microbiology/epidemiology 67
Clinical disease 67
Diagnosis 67
Treatment 67
Drug therapy 67
Drug therapy alternatives 67
Further reading 67
Chapter 58: Cryptosporidium Species 68
Microbiology/epidemiology 68
Clinical disease 68
Diagnosis 68
Treatment 68
Drug therapy 68
Drug therapy alternatives 68
Further reading 68
Chapter 59: Ctenocephalides Species (Fleas) 68
Microbiology/epidemiology 68
Clinical disease 69
Diagnosis 69
Treatment 69
Drug therapy 69
Drug therapy alternatives 69
Further reading 69
Chapter 60: Cuterebra Species (Botfly Larvae) 69
Microbiology/epidemiology 69
Clinical disease 70
Diagnosis 70
Treatment 70
Drug therapy 70
Drug therapy alternatives 70
Further reading 70
Chapter 61: Cytauxzoon Felis 71
Microbiology/epidemiology 71
Clinical disease 71
Diagnosis 71
Treatment 71
Drug therapy 71
Further reading 71
Chapter 62: Dematiaceous Fungi (Phaeohypomycosis, Chromoblastomycosis) 71
Microbiology/epidemiology 72
Clinical disease 72
Diagnosis 72
Treatment 72
Drug therapy 72
Drug therapy alternatives 72
Further reading 72
Chapter 63: Demodex Canis/Felis (Red Mange) 72
Microbiology/epidemiology 72
Clinical disease 73
Diagnosis 73
Treatment 73
Drug therapy 73
Drug therapy alternatives 73
Further reading 73
Chapter 64: Dermatophytosis 73
Microbiology/epidemiology 74
Clinical disease 74
Diagnosis 74
Treatment 74
Drug therapy 74
Drug therapy alternatives 74
Further reading 74
Chapter 65: Dipylidium Caninum (Flea Tapeworm) 74
Microbiology/epidemiology 74
Clinical disease 75
Diagnosis 75
Treatment 75
Drug therapy 75
Drug therapy alternatives 75
Further reading 75
Chapter 66: Dirofilaria Immitis (Heartworm) 75
Microbiology/epidemiology 75
Clinical disease 75
Diagnosis 76
Treatment 76
Drug therapy 76
Drug therapy alternatives 76
Further reading 76
Chapter 67: Distemper (Canine) 76
Microbiology/epidemiology 77
Clinical disease 77
Diagnosis 77
Treatment 77
Drug therapy 77
Drug therapy alternatives 77
Further reading 77
Chapter 68: Ehrlichia Species 77
Microbiology/epidemiology 77
Clinical disease 78
Diagnosis 78
Treatment 78
Drug therapy 78
Drug therapy alternatives 78
Further reading 78
Chapter 69: Entamoeba Histolytica 78
Microbiology/epidemiology 78
Clinical disease 79
Diagnosis 79
Treatment 79
Drug therapy 79
Drug therapy alternatives 79
Further reading 79
Chapter 70: Enterobacter Species 79
Microbiology/epidemiology 79
Clinical disease 79
Diagnosis 80
Treatment 80
Drug therapy 80
Drug therapy alternatives 80
Further reading 80
Chapter 71: Enterococcus 80
Microbiology/epidemiology 80
Clinical disease 80
Diagnosis 80
Treatment 80
Drug therapy 81
Drug therapy alternatives 81
Further reading 81
Chapter 72: Erysipelothrix Species 81
Microbiology/epidemiology 81
Clinical disease 81
Diagnosis 81
Treatment 81
Drug therapy 82
Drug therapy alternatives 82
Further reading 82
Chapter 73: Escherichia Coli (Enterotoxigenic/Enterohemorrhagic) 82
Microbiology/epidemiology 82
Clinical disease 82
Diagnosis 82
Treatment 82
Drug therapy 83
Drug therapy alternatives 83
Further reading 83
Chapter 74: Eschericha Coli (Nonenterohemorrhagic) 83
Microbiology/epidemiology 83
Clinical disease 83
Diagnosis 83
Treatment 83
Drug therapy 83
Drug therapy alternatives 84
Further reading 84
Chapter 75: Feline Coronovirus (Feline Infectious Peritonitis: FIP) 84
Microbiology/epidemiology 84
Clinical disease 84
Diagnosis 84
Treatment 84
Drug therapy 85
Further reading 85
Chapter 76: Feline Immunodeficiency Virus (FIV) 85
Microbiology/epidemiology 85
Clinical disease 85
Diagnosis 85
Treatment 85
Drug therapy 85
Drug therapy alternatives 85
Further reading 86
Chapter 77: Feline Leukemia Virus (FeLV) 86
Microbiology/epidemiology 86
Clinical disease 86
Diagnosis 86
Treatment 86
Drug therapy 86
Drug therapy alternatives 86
Further reading 86
Chapter 78: Feline Panleukopenia Virus 87
Microbiology/epidemiology 87
Clinical disease 87
Diagnosis 87
Treatment 87
Drug therapy 87
Further reading 87
Chapter 79: Francisella Tularensis (Tularemia) 87
Microbiology/epidemiology 87
Clinical disease 88
Diagnosis 88
Treatment 88
Drug therapy 88
Drug therapy alternatives 88
Further reading 88
Chapter 80: Fusarium Species 88
Microbiology/epidemiology 88
Clinical disease 88
Diagnosis 89
Treatment 89
Drug therapy 89
Further reading 89
Chapter 81: Giardia Species 89
Microbiology/epidemiology 89
Clinical disease 89
Diagnosis 89
Treatment 89
Drug therapy 90
Drug therapy alternatives 90
Further reading 90
Chapter 82: Helicobacter Species 90
Microbiology/epidemiology 90
Clinical disease 90
Diagnosis 90
Treatment 90
Drug therapy 90
Drug therapy alternatives 90
Further reading 91
Chapter 83: Hepatozoon Americanum/Canis (Hepatozoonosis) 91
Microbiology/epidemiology 91
Clinical disease 91
Diagnosis 91
Treatment 91
Drug therapy 91
Drug therapy alternatives 91
Further reading 92
Chapter 84: Herpes Virus (Canine) 92
Microbiology/epidemiology 92
Clinical disease 92
Diagnosis 92
Treatment 92
Drug therapy 92
Drug therapy alternatives 92
Further reading 92
Chapter 85: Histoplasma Capsulatum 92
Microbiology/epidemiology 92
Clinical disease 93
Diagnosis 93
Treatment 93
Drug therapy 93
Drug therapy alternatives 93
Further reading 93
Chapter 86: Hyalohyphomycosis (Paecilomyces/Scedosporium) 93
Microbiology/epidemiology 94
Clinical disease 94
Diagnosis 94
Treatment 94
Drug therapy 94
Drug therapy alternatives 94
Further reading 94
Chapter 87: Isospora Species 94
Microbiology/epidemiology 94
Clinical disease 95
Diagnosis 95
Treatment 95
Drug therapy 95
Drug therapy alternatives 95
Further reading 95
Chapter 88: Klebsiella Species 95
Microbiology/epidemiology 95
Clinical disease 95
Diagnosis 95
Treatment 96
Drug therapy 96
Drug therapy alternatives 96
Further reading 96
Chapter 89: Leishmaniosis 96
Microbiology/epidemiology 96
Clinical disease 96
Diagnosis 96
Treatment 97
Drug therapy 97
Drug therapy alternatives 97
Further reading 97
Chapter 90: Leptospira Species 97
Microbiology/epidemiology 97
Clinical disease 97
Diagnosis 98
Treatment 98
Drug therapy 98
Drug therapy alternatives 98
Further reading 98
Chapter 91: Lice 98
Microbiology/epidemiology 98
Clinical disease 98
Diagnosis 98
Treatment 98
Drug therapy 99
Drug therapy alternatives 99
Further reading 99
Chapter 92: Malassezia 99
Microbiology/epidemiology 99
Clinical disease 99
Diagnosis 99
Treatment 99
Drug therapy 99
Drug therapy alternatives 99
Further reading 99
Chapter 93: Microsporidia 100
Microbiology/epidemiology 100
Clinical disease 100
Diagnosis 100
Treatment 100
Drug therapy 100
Drug therapy alternatives 100
Further reading 100
Chapter 94: Mucor Species 101
Microbiology/epidemiology 101
Clinical disease 101
Diagnosis 101
Treatment 101
Drug therapy 101
Drug therapy alternatives 101
Further reading 101
Chapter 95: Mycobacterium Species 102
Microbiology/epidemiology 102
Clinical disease 102
Diagnosis 102
Treatment 102
Drug therapy 102
Further reading 103
Chapter 96: Mycoplasma Species 103
Microbiology/epidemiology 103
Clinical disease 103
Diagnosis 103
Treatment 103
Drug therapy 103
Further reading 104
Chapter 97: Myiasis (Maggots) 104
Microbiology/epidemiology 104
Clinical disease 104
Diagnosis 104
Treatment 104
Drug therapy 104
Further reading 104
Chapter 98: Neospora Caninum 104
Microbiology/epidemiology 105
Clinical disease 105
Diagnosis 105
Treatment 105
Drug therapy 105
Further reading 105
Chapter 99: Neorickettsia Helminthoeca 105
Microbiology/epidemiology 105
Clinical disease 106
Diagnosis 106
Treatment 106
Drug therapy 106
Drug therapy alternatives 106
Further reading 106
Chapter 100: Nocardia Species 106
Microbiology/epidemiology 106
Clinical disease 106
Diagnosis 107
Treatment 107
Drug therapy 107
Drug therapy alternatives 107
Further reading 107
Chapter 101: Otodectes Cynotis (Otodectic Mange) 107
Microbiology/epidemiology 107
Clinical Disease 107
Diagnosis 107
Treatment 107
Drug therapy 108
Drug therapy alternatives 108
Further reading 108
Chapter 102: Papilloma Virus 108
Microbiology/epidemiology 108
Clinical disease 108
Diagnosis 108
Treatment 108
Drug therapy 108
Drug therapy alternatives 109
Further reading 109
Chapter 103: Paragonimus Species (Liver Flukes) 109
Microbiology/epidemiology 109
Clinical disease 109
Diagnosis 109
Treatment 109
Drug therapy 109
Drug therapy alternatives 109
Further reading 109
Chapter 104: Parvovirus 109
Microbiology/epidemiology 110
Clinical disease 110
Diagnosis 110
Treatment 110
Drug therapy 110
Drug therapy alternatives 110
Further reading 110
Chapter 105: Pasteurella Species 110
Microbiology/epidemiology 110
Clinical disease 111
Diagnosis 111
Treatment 111
Drug therapy 111
Drug therapy alternatives 111
Further reading 111
Chapter 106: Poxvirus 111
Microbiology/epidemiology 111
Clinical disease 111
Diagnosis 112
Treatment 112
Drug therapy 112
Drug therapy alternatives 112
Further reading 112
Chapter 107: Proteus Species 112
Microbiology/epidemiology 112
Clinical disease 112
Diagnosis 112
Treatment 112
Drug therapy 113
Drug therapy alternatives 113
Further reading 113
Chapter 108: Prototheca Species 113
Microbiology/epidemiology 113
Clinical disease 113
Diagnosis 113
Treatment 113
Drug therapy 114
Drug therapy alternatives 114
Further reading 114
Chapter 109: Pseudomonas Aeruginosa 114
Microbiology/epidemiology 114
Clinical disease 114
Diagnosis 114
Treatment 114
Drug therapy 115
Drug therapy alternatives 115
Further reading 115
Chapter 110: Pseudorabies (Aujeszky’s Disease) 115
Microbiology/epidemiology 115
Clinical disease 115
Diagnosis 115
Treatment 115
Further reading 115
Chapter 111: Rabies Virus 116
Microbiology/epidemiology 116
Clinical disease 116
Diagnosis 116
Treatment 116
Further reading 116
Chapter 112: Rhodococcus Equi 116
Microbiology/epidemiology 116
Clinical disease 117
Diagnosis 117
Treatment 117
Drug therapy 117
Drug therapy alternatives 117
Further reading 117
Chapter 113: Rickettsia Rickettsii (Rocky Mountain Spotted Fever) 117
Microbiology/epidemiology 117
Clinical disease 117
Diagnosis 118
Treatment 118
Drug therapy 118
Drug therapy alternatives 118
Further reading 118
Chapter 114: Salmonella Species 118
Microbiology/epidemiology 118
Clinical disease 118
Diagnosis 119
Treatment 119
Drug therapy 119
Drug therapy alternatives 119
Further reading 119
Chapter 115: Sarcoptes Scabiei (Sarcoptic Mange) 119
Microbiology/epidemiology 119
Clinical disease 119
Diagnosis 119
Treatment 120
Drug therapy 120
Drug therapy alternatives 120
Further reading 120
Chapter 116: Serratia Species 120
Microbiology/epidemiology 120
Clinical disease 120
Diagnosis 120
Treatment 121
Drug therapy 121
Drug therapy alternatives 121
Further reading 121
Chapter 117: Shigella Species 121
Microbiology/epidemiology 121
Clinical disease 121
Diagnosis 121
Treatment 121
Drug therapy 122
Drug therapy alternatives 122
Further reading 122
Chapter 118: Sporothrix Species 122
Microbiology/epidemiology 122
Clinical disease 122
Diagnosis 122
Treatment 122
Drug therapy 122
Drug therapy alternatives 122
Further reading 122
Chapter 119: Staphylococcus Species 123
Microbiology/epidemiology 123
Clinical disease 123
Diagnosis 123
Treatment 123
Drug therapy 123
Drug therapy alternatives 124
Further reading 124
Chapter 120: Streptococcus Species 124
Microbiology/epidemiology 124
Clinical disease 124
Diagnosis 124
Treatment 124
Drug therapy 124
Drug therapy alternatives 124
Further reading 124
Chapter 121: Strongyloides Species (Threadworms) 125
Microbiology/epidemiology 125
Clinical disease 125
Diagnosis 125
Treatment 125
Drug therapy 125
Further reading 125
Chapter 122: Toxocara Canis/Cati 126
Microbiology/epidemiology 126
Clinical disease 126
Diagnosis 126
Treatment 126
Drug therapy 126
Drug therapy alternatives 126
Further reading 126
Chapter 123: Toxoplasma Gondii (Toxoplasmosis) 127
Microbiology/epidemiology 127
Clinical disease 127
Diagnosis 127
Treatment 127
Drug therapy 127
Drug therapy alternatives 127
Further reading 127
Chapter 124: Trichomonas Species 127
Microbiology/epidemiology 128
Clinical disease 128
Diagnosis 128
Treatment 128
Drug therapy 128
Drug therapy alternatives 128
Further reading 128
Chapter 125: Yersinia Pestis (Plaque) 128
Microbiology/epidemiology 128
Clinical disease 128
Diagnosis 129
Treatment 129
Drug therapy 129
Drug therapy alternatives 129
Further reading 129
Section D Antibiotics 130
Chapter 126: Amikacin 130
Use 130
Contraindications/warnings 130
Dosage 130
Dose adjustments 130
Administration 130
Electrolyte contents 131
Storage/stability 131
Adverse reactions 131
Drug interactions 131
Monitoring 131
Overdose 131
Diagnostic test interference 131
Mechanism 131
Pharmacology/kinetics 132
Pregnancy risk factor 132
References 132
Further reading 132
Chapter 127: Amoxicillin 132
Use 132
Contraindications/warnings 133
Dosage 133
Dose adjustments 133
Administration 133
Electrolyte contents 133
Storage/stability 133
Adverse reactions 133
Drug interactions 133
Monitoring 133
Overdose 133
Diagnostic test interference 133
Mechanism 133
Pharmacology/kinetics 133
Pregnancy risk factor 134
Further reading 134
Chapter 128: Ampicillin 134
Use 134
Contraindications/warnings 134
Dosage 134
Dose adjustments 135
Administration 135
Electrolyte contents 135
Storage/stability 135
Adverse reactions 135
Drug interactions 135
Monitoring 135
Overdose 135
Diagnostic test interference 135
Pharmacology/kinetics 135
Pregnancy risk factor 136
Reference 136
Further reading 136
Chapter 129: Azithromycin 136
Use 136
Contraindications/warnings 136
Dosage 136
Dose adjustments 137
Administration 137
Electrolyte contents 137
Storage/stability 137
Adverse reactions 137
Drug interactions 137
Monitoring 137
Overdose 137
Diagnostic test interference 137
Mechanism 137
Pharmacology/kinetics 138
Pregnancy risk factor 138
References 138
Chapter 130: Cefadroxil 138
Use 138
Contraindications/warnings 138
Dosage 139
Dose adjustments 139
Administration 139
Electrolyte contents 139
Storage/stability 139
Adverse reactions 139
Drug interactions 139
Monitoring 139
Overdose 139
Diagnostic test interference 139
Mechanism 139
Pharmacology/kinetics 139
Pregnancy risk factor 140
Reference 140
Further reading 140
Chapter 131: Cefazolin 140
Use 140
Contraindications/warnings 140
Dosage 140
Dose adjustments 140
Administration 140
Electrolyte contents 141
Storage/stability 141
Adverse reactions 141
Drug interactions 141
Monitoring 141
Overdose 141
Diagnostic test interference 141
Mechanism 141
Pharmacology/kinetics 141
Pregnancy risk factor 142
Reference 142
Further reading 142
Chapter 132: Cefdinir 142
Use 142
Contraindications/warnings 142
Dosage 142
Dose adjustments 142
Administration 143
Electrolyte contents 143
Storage/stability 143
Adverse reactions 143
Drug interactions 143
Monitoring 143
Overdose 143
Diagnostic test interference 143
Mechanism 143
Pharmacology/kinetics 143
Pregnancy risk factor 144
Reference 144
Further reading 144
Chapter 133: Cefepime 144
Use 144
Contraindications/warnings 144
Dosage 144
Dose adjustments 144
Administration 144
Electrolyte contents 145
Storage/stability 145
Adverse reactions 145
Drug interactions 145
Monitoring 145
Overdose 145
Diagnostic test interference 145
Mechanism 145
Pharmacology/kinetics 145
Pregnancy risk factor 146
Reference 146
Further reading 146
Chapter 134: Cefotaxime 146
Use 146
Contraindications/warnings 146
Dosage 146
Dose adjustments 146
Administration 146
Electrolyte contents 147
Storage/stability 147
Adverse reactions 147
Drug interactions 147
Monitoring 147
Overdose 147
Diagnostic test interference 147
Mechanism 147
Pharmacology/kinetics 147
Pregnancy risk factor 148
References 148
Chapter 135: Cefovecin 148
Use 148
Contraindications/warnings 148
Dosage 148
Dose adjustments 149
Administration 149
Electrolyte contents 149
Storage/stability 149
Adverse reactions 149
Drug interactions 149
Monitoring 149
Overdose 149
Diagnostic test interference 149
Mechanism 149
Pharmacology/kinetics 149
Pregnancy risk factor 150
Further reading 150
Chapter 136: Cefoxitin 150
Use 150
Contraindications/warnings 150
Dosage 150
Dose adjustments 150
Administration 150
Electrolyte contents 151
Storage/stability 151
Adverse reactions 151
Drug interactions 151
Monitoring 151
Overdose 151
Diagnostic test interference 151
Mechanism 151
Pharmacology/kinetics 151
Pregnancy risk factor 151
Reference 152
Further reading 152
Chapter 137: Cefpodoxime 152
Use 152
Contraindications/warnings 152
Dosage 152
Dose adjustments 152
Administration 152
Electrolyte contents 152
Storage/stability 152
Adverse reactions 152
Drug interactions 153
Monitoring 153
Overdose 153
Diagnostic test interference 153
Mechanism 153
Pharmacology/kinetics 153
Pregnancy risk factor 153
Reference 153
Further reading 153
Chapter 138: Ceftazidime 154
Use 154
Contraindications/warnings 154
Dosage 154
Dose adjustments 154
Administration 154
Electrolyte contents 154
Storage/stability 154
Adverse reactions 154
Drug interactions 154
Monitoring 155
Overdose 155
Diagnostic test interference 155
Mechanism 155
Pharmacology/kinetics 155
Pregnancy risk factor 155
Reference 155
Further reading 155
Chapter 139: Ceftiofur 155
Use 156
Contraindications/warnings 156
Dosage 156
Dose adjustments 156
Administration 156
Electrolyte contents 156
Storage/stability 156
Adverse reactions 156
Drug interactions 156
Monitoring 156
Overdose 156
Diagnostic test interference 156
Mechanism 157
Pharmacology/kinetics 157
Pregnancy risk factor 157
Reference 157
Further reading 157
Chapter 140: Cefuroxime 157
Use 157
Contraindications/warnings 157
Dosage 157
Dose adjustments 158
Administration 158
Electrolyte contents 158
Storage/stability 158
Adverse reactions 158
Drug interactions 158
Monitoring 158
Overdose 158
Diagnostic test interference 158
Mechanism 159
Pharmacology/kinetics 159
Pregnancy risk factor 159
Reference 159
Further reading 159
Chapter 141: Cephalexin 159
Use 159
Contraindications/warnings 159
Dosage 159
Dose adjustment 160
Administration 160
Electrolyte contents 160
Storage/stability 160
Adverse reactions 160
Drug interactions 160
Monitoring 160
Overdose 160
Diagnostic test interference 160
Mechanism 160
Pharmacology/kinetics 160
Pregnancy risk factor 161
References 161
Further reading 161
Chapter 142: Chloramphenicol 161
Use 161
Contraindications/warnings 161
Dosage 161
Dose adjustments 162
Administration 162
Electrolyte contents 162
Storage/stability 162
Adverse reactions 162
Drug interactions 162
Monitoring 162
Overdose 162
Diagnostic test interference 162
Mechanism 162
Pharmacology/kinetics 162
Pregnancy risk factor 163
References 163
Further reading 163
Chapter 143: Ciprofloxacin 163
Use 163
Contraindications/warnings 163
Dosage 164
Dose adjustments 164
Administration 164
Electrolyte contents 164
Storage/stability 164
Adverse reactions 164
Drug interactions 164
Monitoring 164
Overdose 164
Diagnostic test interference 165
Mechanism 165
Pharmacology/kinetics 165
Pregnancy risk factor 165
Reference 165
Further reading 165
Chapter 144: Clarithromycin 165
Use 165
Contraindications/warnings 165
Dosage 165
Dose adjustments 166
Administration 166
Electrolyte contents 166
Storage/stability 166
Adverse reactions 166
Drug interactions 166
Monitoring 166
Overdose 166
Diagnostic test interference 166
Mechanism 166
Pharmacology/kinetics 166
Pregnancy risk factor 167
References 167
Further reading 167
Chapter 145: Clavamox 167
Use 167
Contraindications/warnings 167
Dosage 167
Dose adjustments 168
Administration 168
Electrolyte contents 168
Storage/stability 168
Adverse reactions 168
Drug interactions 168
Monitoring 168
Overdose 168
Diagnostic test interference 168
Mechanism 168
Pharmacology/kinetics 169
Pregnancy risk factor 169
References 169
Further reading 169
Chapter 146: Clindamycin 169
Use 169
Contraindications/warnings 170
Dosage 170
Dose adjustments 170
Administration 170
Electrolyte contents 170
Storage/stability 170
Adverse reactions 170
Drug interactions 170
Monitoring 170
Overdose 170
Diagnostic test interference 171
Mechanism 171
Pharmacology/kinetics 171
Pregnancy risk factor 171
References 171
Further reading 171
Chapter 147: Dicloxacillin 171
Use 171
Contraindications/warnings 171
Dosage 172
Dose adjustments 172
Administration 172
Electrolyte contents 172
Storage/stability 172
Adverse reactions 172
Drug interactions 172
Monitoring 172
Overdose 172
Diagnostic test interference 172
Mechanism 172
Pharmacology/kinetics 172
Pregnancy risk factor 173
Reference 173
Further reading 173
Chapter 148: Doxycycline 173
Use 173
Contraindications/warnings 173
Dosage 173
Dose adjustments 173
Administration 173
Electrolyte contents 174
Storage/stability 174
Adverse reactions 174
Drug interactions 174
Monitoring 174
Overdose 174
Diagnostic test interference 174
Mechanism 174
Pharmacology/kinetics 174
Pregnancy risk factor 175
References 175
Further reading 175
Chapter 149: Enrofloxacin 175
Use 175
Contraindications/warnings 175
Dosage 176
Dose adjustments 176
Administration 176
Electrolyte contents 176
Storage/stability 176
Adverse reactions 176
Drug interactions 176
Monitoring 177
Overdose 177
Diagnostic test interference 177
Mechanism 177
Pharmacology/kinetics 177
Pregnancy risk factor 177
References 177
Further reading 177
Chapter 150: Erythromycin 178
Use 178
Contraindications/warnings 178
Dosage 178
Dose adjustments 178
Administration 178
Electrolyte contents 178
Storage/stability 178
Drug interactions 179
Monitoring 179
Overdose 179
Diagnostic test interference 179
Mechanism 179
Pharmacology/kinetics 179
Pregnancy risk factor 179
References 179
Further reading 180
Chapter 151: Florfenicol 180
Use 180
Contraindications/warnings 180
Dosage 180
Dose adjustments 180
Administration 180
Electrolyte contents 180
Storage/stability 180
Adverse reactions 181
Drug interactions 181
Monitoring 181
Overdose 181
Diagnostic test interference 181
Mechanism 181
Pharmacology/kinetics 181
Pregnancy risk factor 181
Reference 181
Further reading 181
Chapter 152: Gentamicin 182
Use 182
Contraindications/warnings 182
Dosage 182
Dose adjustments 182
Administration 182
Electrolyte contents 182
Storage/stability 182
Adverse reactions 183
Drug interactions 183
Monitoring 183
Overdose 183
Diagnostic test interference 183
Mechanism 183
Pharmacology/kinetics 183
Pregnancy risk factor 184
Reference 184
Further reading 184
Chapter 153: Imipenem and Cilastatin 184
Use 184
Contraindications/warnings 184
Dosage 184
Dose adjustments 184
Administration 184
Electrolyte contents 185
Storage/stability 185
Adverse reactions 185
Drug interactions 185
Monitoring 185
Overdose 185
Diagnostic test interference 185
Mechanism 185
Pharmacology/kinetics 185
Pregnancy risk factor 186
Reference 186
Further reading 186
Chapter 154: Linezolid 186
Use 186
Contraindications/warnings 186
Dosage 186
Dose adjustments 186
Administration 187
Electrolyte contents 187
Storage/stability 187
Adverse reactions 187
Drug interactions 187
Monitoring 187
Overdose 187
Diagnostic test interference 187
Mechanism 187
Pharmacology/kinetics 187
Pregnancy risk factor 188
Reference 188
Further reading 188
Chapter 155: Marbofloxacin 188
Use 188
Contraindications/warnings 188
Dosage 188
Dose adjustments 188
Administration 188
Electrolyte contents 189
Storage/stability 189
Adverse reactions 189
Drug interactions 189
Monitoring 189
Overdose 189
Diagnostic test interference 189
Mechanism 189
Pharmacology/kinetics 189
Pregnancy risk factor 190
Further reading 190
Chapter 156: Meropenem 190
Use 190
Contraindications/warnings 190
Dosage 190
Dose adjustments 190
Administration 190
Electrolyte contents 191
Storage/stability 191
Adverse reactions 191
Drug interactions 191
Monitoring 191
Overdose 191
Diagnostic test interference 191
Mechanism 191
Pharmacology/kinetics 191
Pregnancy risk factor 192
References 192
Further reading 192
Chapter 157: Metronidazole 192
Use 192
Contraindications/warnings 192
Dosage 192
Dose adjustments 193
Administration 193
Electrolyte contents 193
Storage/stability 193
Adverse reactions 193
Drug interactions 193
Monitoring 193
Overdose 193
Diagnostic test interference 194
Mechanism 194
Pharmacology/kinetics 194
Pregnancy risk factor 194
References 194
Further reading 194
Chapter 158: Minocycline 194
Use 194
Contraindications/warnings 195
Dosage 195
Dose adjustments 195
Administration 195
Electrolyte contents 195
Storage/stability 195
Adverse reactions 195
Drug interactions 195
Monitoring 196
Overdose 196
Diagnostic test interference 196
Mechanism 196
Pharmacology/kinetics 196
Pregnancy risk factor 196
References 196
Further reading 196
Chapter 159: Nitrofurantoin 197
Use 197
Contraindications/warnings 197
Dosage 197
Dose adjustments 197
Administration 197
Electrolyte contents 197
Storage/stability 197
Adverse reactions 197
Drug interactions 198
Monitoring 198
Overdose 198
Diagnostic test interference 198
Mechanism 198
Pharmacology/kinetics 198
Pregnancy risk factor 198
References 198
Further reading 198
Chapter 160: Orbifloxacin 199
Use 199
Contraindications/warning 199
Dosage 199
Dose adjustments 199
Administration 199
Electrolyte contents 199
Storage/stability 199
Adverse reactions 199
Drug interactions 200
Monitoring 200
Overdose 200
Diagnostic test interference 200
Mechanism 200
Pharmacology/kinetics 200
Pregnancy risk factor 200
Further reading 200
Chapter 161: Oxytetracycline 201
Use 201
Contraindications/warnings 201
Dosage 201
Dose adjustments 201
Administration 201
Electrolyte contents 201
Storage/stability 201
Adverse reactions 201
Drug interactions 202
Monitoring 202
Overdose 202
Diagnostic test interference 202
Mechanism 202
Pharmacology/kinetics 202
Pregnancy risk factor 202
Reference 202
Further reading 202
Chapter 162: Penicillin 203
Use 203
Contraindications/warnings 203
Dosage 203
Dose adjustments 203
Administration 203
Electrolyte contents 203
Storage/stability 204
Adverse reactions 204
Drug interactions 204
Monitoring 204
Overdose 204
Diagnostic test interference 204
Mechanism 204
Pharmacology/kinetics 204
Pregnancy risk factor 205
References 205
Further reading 205
Chapter 163: Pradofloxacin 205
Use 205
Contraindications/warnings 205
Dosage 205
Dose adjustments 205
Administration 206
Electrolyte contents 206
Storage/stability 206
Adverse reactions 206
Drug interactions 206
Monitoring 206
Overdose 206
Diagnostic test interference 206
Mechanism 206
Pharmacology/kinetics 206
Pregnancy risk factor 207
Further reading 207
Chapter 164: Rifampin 207
Use 207
Contraindications/warnings 207
Dosage 207
Dose adjustments 208
Administration 208
Electrolyte contents 208
Storage/stability 208
Adverse reactions 208
Drug interactions 208
Monitoring 208
Overdose 208
Diagnostic test interference 208
Mechanism 209
Pharmacology/kinetics 209
Pregnancy risk factor 209
Reference 209
Further reading 209
Chapter 165: Potentiated Sulfas 209
Use 209
Contraindications/warnings 210
Dosage 210
Dose adjustments 210
Administration 210
Electrolyte contents 210
Storage/stability 210
Adverse reactions 210
Drug interactions 211
Monitoring 211
Overdose 211
Diagnostic test interference 211
Mechanism 211
Pharmacology/kinetics 211
Pregnancy risk factor 212
References 212
Further reading 212
Chapter 166: Timentin 212
Use 212
Contraindications/warnings 212
Dosage 213
Dose adjustments 213
Administration 213
Electrolyte contents 213
Storage/stability 213
Adverse reactions 213
Drug interactions 213
Monitoring 213
Overdose 213
Diagnostic test interference 213
Mechanism 214
Pharmacology/Kinetics 214
Pregnancy risk factor 214
Reference 214
Further reading 214
Chapter 167: Tobramycin 214
Use 214
Contraindications/warnings 214
Dosage 215
Dose adjustments 215
Administration 215
Electrolyte contents 215
Storage/stability 215
Adverse reactions 215
Drug interactions 215
Monitoring 215
Overdose 216
Diagnostic test interference 216
Mechanism 216
Pharmacology/kinetics 216
Pregnancy risk factor 216
Reference 216
Further reading 216
Chapter 168: Tylosin 216
Use 217
Contraindications/warnings 217
Dosage 217
Dose adjustments 217
Administration 217
Electrolyte contents 217
Storage/stability 217
Adverse reactions 217
Drug interactions 217
Monitoring 217
Overdose 217
Diagnostic test interference 217
Mechanism 218
Pharmacology/kinetics 218
Pregnancy risk factor 218
Reference 218
Further reading 218
Chapter 169: Unasyn 218
Use 218
Contraindications/warnings 218
Dosage 219
Dose adjustments 219
Administration 219
Electrolyte contents 219
Storage/stability 219
Adverse reactions 219
Drug interactions 219
Monitoring 219
Overdose 219
Diagnostic test interference 219
Mechanism 220
Pharmacology/kinetics 220
Pregnancy risk factor 220
Reference 220
Further reading 220
Chapter 170: Vancomycin 220
Use 220
Contraindications/warnings 221
Dosage 221
Dose adjustments 221
Administration 221
Electrolyte contents 221
Storage/stability 221
Adverse reactions 221
Drug interactions 221
Monitoring 222
Overdose 222
Diagnostic test interference 222
Mechanism 222
Pharmacology/kinetics 222
Pregnancy risk factor 222
Reference 222
Further reading 222
Chapter 171: Zosyn 223
Use 223
Contraindications/warnings 223
Dosage 223
Dose Adjustments 223
Administration 223
Electrolyte contents 223
Storage/stability 223
Adverse reactions 223
Drug interactions 224
Monitoring 224
Overdose 224
Diagnostic test interference 224
Mechanism 224
Pharmacology/kinetics 224
Pregnancy risk factor 224
Reference 224
Further reading 224
Section E Antifungal Agents 233
Chapter 172: Amphotericin B 233
Use 233
Contraindications/warnings 233
Dosage 233
Dose adjustments 234
Administration 234
Electrolyte contents 235
Storage/stability 235
Adverse reactions 235
Drug interactions 235
Monitoring 235
Overdose 235
Diagnostic test interference 235
Mechanism 235
Pharmacology/kinetics 235
Pregnancy risk factor 236
Reference 236
Further reading 236
Chapter 173: Caspofungin 236
Use 236
Contraindications/warnings 236
Dosage 237
Dose adjustments 237
Administration 237
Electrolyte contents 237
Storage/stability 237
Adverse reactions 237
Drug interactions 237
Monitoring 237
Overdose 237
Diagnostic test interference 237
Mechanism 237
Pharmacology/kinetics 238
Pregnancy risk factor 238
Reference 238
Further reading 238
Chapter 174: Clotrimazole 238
Use 238
Contraindications/warnings 238
Dosage 239
Dose adjustments 239
Administration 239
Electrolyte contents 239
Storage/stability 239
Adverse reactions 239
Drug interactions 239
Monitoring 239
Overdose 239
Diagnostic test interference 240
Mechanism 240
Pharmacology/kinetics 240
Pregnancy risk factor 240
References 240
Further reading 240
Chapter 175: Enilconazole 240
Use 240
Contraindications/warnings 241
Dosage 241
Dose adjustments 241
Administration 241
Electrolyte contents 241
Storage/stability 241
Adverse reactions 241
Drug interactions 241
Monitoring 241
Overdose 241
Diagnostic test interference 241
Mechanism 242
Pharmacology/kinetics 242
Pregnancy risk factor 242
Reference 242
Further reading 242
Chapter 176: Fluconazole 242
Use 242
Contraindications/warnings 243
Dosage 243
Dose adjustments 243
Administration 243
Electrolyte contents 243
Storage/stability 243
Adverse reactions 243
Drug interactions 243
Monitoring 243
Overdose 243
Diagnostic test interference 244
Mechanism 244
Pharmacology/kinetics 244
Pregnancy risk factor 244
Reference 244
Further reading 244
Chapter 177: Flucytosine 244
Use 244
Contraindications/warnings 245
Dosage 245
Dose adjustments 245
Administration 245
Electrolyte contents 245
Storage/stability 245
Adverse reactions 245
Drug interactions 245
Monitoring 245
Overdose 246
Diagnostic test interference 246
Mechanism 246
Pharmacology/kinetics 246
Pregnancy risk factor 246
References 246
Further reading 246
Chapter 178: Itraconazole 246
Use 246
Contraindications/warnings 247
Dosage 247
Dose adjustments 247
Administration 247
Electrolyte contents 247
Storage/stability 247
Adverse reactions 247
Drug interactions 247
Monitoring 248
Overdose 248
Diagnostic test interference 248
Mechanism 248
Pharmacology/kinetics 248
Pregnancy risk factor 248
References 248
Further reading 248
Chapter 179: Ketoconazole 249
Use 249
Contraindications/warnings 249
Dosage 249
Dose adjustments 249
Administration 249
Electrolyte contents 249
Storage/stability 249
Adverse reactions 249
Drug interactions 250
Monitoring 250
Overdose 250
Diagnostic test interference 250
Mechanism 250
Pharmacology/kinetics 250
Pregnancy risk factor 250
Reference 250
Further reading 250
Chapter 180: Posaconazole 251
Use 251
Contraindications/warnings 251
Dosage 251
Dose adjustment 251
Administration 251
Electrolyte contents 252
Storage/stability 252
Adverse reactions 252
Drug interactions 252
Monitoring 252
Overdose 252
Diagnostic test interference 252
Mechanism 252
Pharmacology/kinetics 252
Pregnancy risk factor 253
References 253
Further reading 253
Chapter 181: Terbinafine 253
Use 253
Contraindications/warnings 253
Dosage 253
Dose adjustments 253
Administration 253
Electrolyte contents 254
Storage/stability 254
Adverse reactions 254
Drug interactions 254
Monitoring 254
Overdose 254
Diagnostic test interference 254
Mechanism 254
Pharmacology/kinetics 254
Pregnancy risk factor 255
References 255
Further reading 255
Chapter 182: Voriconazole 255
Use 255
Contraindications/warnings 255
Dosage 255
Dose adjustments 256
Administration 256
Electrolyte contents 256
Storage/stability 256
Adverse reactions 256
Drug interactions 256
Monitoring 257
Overdose 257
Diagnostic test interference 257
Mechanism 257
Pharmacology/kinetics 257
Pregnancy risk factor 257
References 257
Further reading 258
Section F Antiparasitic Agents 259
Chapter 183: Albendazole 259
Use 259
Contraindications/warnings 259
Dosage 259
Dose adjustments 259
Administration 259
Electrolyte contents 259
Storage/stability 259
Adverse reactions 259
Drug interactions 260
Monitoring 260
Overdose 260
Diagnostic test interference 260
Mechanism 260
Pharmacology/kinetics 260
Pregnancy risk factor 260
References 260
Further reading 261
Chapter 184: Atovaquone 261
Use 261
Contraindications/warnings 261
Dosage 261
Dose adjustments 261
Administration 261
Electrolyte contents 261
Storage/stability 261
Adverse reactions 261
Drug interactions 262
Monitoring 262
Overdose 262
Diagnostic test interference 262
Mechanism 262
Pharmacology/kinetics 262
Pregnancy risk factor 262
References 262
Further reading 262
Chapter 185: Fenbendazole 263
Use 263
Contraindications/warnings 263
Dosage 263
Dose adjustments 263
Administration 263
Electrolyte contents 263
Storage/stability 263
Adverse reactions 263
Drug interactions 264
Monitoring 264
Overdose 264
Diagnostic test interference 264
Mechanism 264
Pharmacology/kinetics 264
Pregnancy risk factor 264
References 264
Further reading 265
Chapter 186: Fipronil 265
Use 265
Contraindications/warnings 265
Dosage 265
Dose adjustments 265
Administration 265
Electrolyte contents 265
Storage/stability 266
Adverse reactions 266
Drug interactions 266
Monitoring 266
Overdose 266
Diagnostic test interference 266
Mechanism 266
Pharmacology/kinetics 266
Pregnancy risk factor 267
Reference 267
Further reading 267
Chapter 187: Imidacloprid 267
Use 267
Contraindications/warnings 267
Dosage 267
Dose adjustments 268
Administration 268
Electrolyte contents 268
Storage/stability 268
Adverse reactions 268
Drug interactions 268
Monitoring 268
Overdose 268
Diagnostic test interference 268
Mechanism 268
Pharmacology/kinetics 268
Pregnancy risk factor 269
Further reading 269
Chapter 188: Imidocarb Dipropionate 269
Use 269
Contraindications/warnings 269
Dosage 269
Dose adjustments 270
Administration 270
Electrolyte contents 270
Storage/stability 270
Adverse reactions 270
Drug interactions 270
Monitoring 270
Overdose 270
Diagnostic test interference 270
Mechanism 270
Pharmacology/kinetics 270
Pregnancy risk factor 271
References 271
Further reading 271
Chapter 189: Ivermectin 271
Use 271
Contraindications/warnings 272
Dosage 272
Dose adjustments 272
Administration 272
Electrolyte contents 272
Storage/stability 272
Adverse reactions 272
Drug interactions 273
Monitoring 273
Overdose 273
Diagnostic test interference 273
Mechanism 273
Pharmacology/kinetics 273
Pregnancy risk factor 273
References 273
Further reading 274
Chapter 190: Lufenuron 274
Use 274
Contraindications/warnings 274
Dosage 274
Dose adjustments 274
Administration 274
Electrolyte contents 274
Storage/stability 274
Adverse reactions 275
Drug interactions 275
Monitoring 275
Overdose 275
Diagnostic test interference 275
Mechanism 275
Pharmacology/kinetics 275
Pregnancy risk factor 275
Reference 275
Further reading 275
Chapter 191: Meglumine Antimoniate 275
Use 276
Contraindications/warnings 276
Dosage 276
Dose adjustments 276
Administration 276
Electrolyte contents 276
Storage/stability 276
Adverse reactions 276
Drug interactions 276
Monitoring 276
Overdose 276
Diagnostic test interference 276
Mechanism 277
Pharmacology/kinetics 277
Pregnancy risk factor 277
Reference 277
Further reading 277
Chapter 192: Melarsomine 277
Use 277
Contraindications/warnings 278
Dosage 278
Dose adjustments 278
Administration 278
Electrolyte contents 278
Storage/stability 278
Adverse reactions 278
Drug interactions 278
Monitoring 279
Overdose 279
Diagnostic test interference 279
Mechanism 279
Pharmacology/kinetics 279
Pregnancy risk factor 279
Further reading 279
Chapter 193: Miltefosine 280
Use 280
Contraindications/warnings 280
Dosage 280
Dose adjustments 280
Administration 280
Electrolyte contents 280
Storage/stability 280
Adverse reactions 280
Drug interactions 280
Monitoring 281
Overdose 281
Diagnostic test interference 281
Mechanism 281
Pharmacology/kinetics 281
Pregnancy risk factor 281
Reference 281
Further reading 281
Chapter 194: Milbemycin Oxime 281
Use 282
Contraindications/warnings 282
Dosage 282
Dose adjustments 282
Administration 282
Electrolyte contents 282
Storage/stability 282
Adverse reactions 282
Drug interactions 282
Monitoring 283
Overdose 283
Diagnostic test interference 283
Mechanism 283
Pharmacology/kinetics 283
Pregnancy risk factor 283
References 283
Further reading 283
Chapter 195: Moxidectin 284
Use 284
Contraindications/warnings 284
Dosage 284
Dose adjustments 284
Administration 284
Electrolyte contents 285
Storage/stability 285
Adverse reactions 285
Drug interactions 285
Monitoring 285
Overdose 285
Diagnostic test interference 285
Mechanism 285
Pharmacology/kinetics 286
Pregnancy risk factor 286
Reference 286
Further reading 286
Chapter 196: Nitazoxanide 286
Use 286
Contraindications/warnings 286
Dosage 287
Dose adjustments 287
Administration 287
Electrolyte contents 287
Storage/stability 287
Adverse reactions 287
Drug interactions 287
Monitoring 287
Overdose 287
Diagnostic test interference 287
Mechanism 287
Pharmacology/kinetics 287
Pregnancy risk factor 288
References 288
Further reading 288
Chapter 197: Nitenpyram 288
Use 288
Contraindications/warnings 288
Dosage 288
Dose adjustments 289
Administration 289
Electrolyte contents 289
Storage/stability 289
Adverse reactions 289
Drug interactions 289
Monitoring 289
Overdose 289
Diagnostic test interference 289
Mechanism 289
Pharmacology/kinetics 289
Pregnancy risk factor 290
Reference 290
Further reading 290
Chapter 198: Ponazuril (Toltrazuril Sulfone) 290
Use 290
Contraindications/warnings 290
Dosage 290
Dose adjustments 291
Administration 291
Electrolyte contents 291
Storage/stability 291
Adverse reactions 291
Drug interactions 291
Monitoring 291
Overdose 291
Diagnostic test interference 291
Mechanism 291
Pharmacology/kinetics 291
Pregnancy risk factor 291
Lactation 292
References 292
Further reading 292
Chapter 199: Praziquantel 292
Use 292
Contraindications/warnings 292
Dosage 292
Dose adjustments 292
Administration 293
Electrolyte contents 293
Storage/stability 293
Adverse reactions 293
Drug interactions 293
Monitoring 293
Overdose 293
Diagnostic test interference 293
Mechanism 293
Pharmacology/kinetics 293
Pregnancy risk factor 293
References 293
Further reading 294
Chapter 200: Primaquine Phosphate 294
Use 294
Contraindications/warnings 294
Dosage 294
Dose adjustments 294
Administration 294
Electrolyte contents 294
Storage/stability 294
Adverse reactions 294
Drug interactions 294
Monitoring 295
Overdose 295
Diagnostic test interference 295
Mechanism 295
Pharmacology/kinetics 295
Pregnancy risk factor 295
Reference 295
Further reading 295
Chapter 201: Pyrantel Pamoate 295
Use 296
Contraindications/warnings 296
Dosage 296
Dose adjustments 296
Administration 296
Electrolyte contents 296
Storage/stability 296
Adverse reactions 296
Drug interactions 296
Monitoring 296
Overdose 296
Diagnostic test interference 296
Mechanism 297
Pharmacology/kinetics 297
Pregnancy risk factor 297
References 297
Further reading 297
Chapter 202: Ronidazole 297
Use 297
Contraindications/warnings 297
Dosage 298
Dose adjustments 298
Administration 298
Electrolyte contents 298
Storage/stability 298
Adverse reactions 298
Drug interactions 298
Monitoring 298
Overdose 298
Diagnostic test interference 298
Mechanism 298
Pharmacology/kinetics 298
Pregnancy risk factor 299
Reference 299
Further reading 299
Chapter 203: Selamectin 299
Use 299
Contraindications/warnings 299
Dosage 299
Dose adjustments 299
Administration 299
Electrolyte contents 300
Storage/stability 300
Adverse reactions 300
Drug interactions 300
Monitoring 300
Overdose 300
Diagnostic test interference 300
Mechanism 300
Pharmacology/kinetics 300
Pregnancy risk factor 301
Reference 301
Further reading 301
Chapter 204: Spinosid 301
Use 301
Contraindications/warnings 301
Dosage 302
Dose adjustments 302
Administration 302
Electrolyte contents 302
Storage/stability 302
Adverse reactions 302
Drug interactions 302
Monitoring 302
Overdose 302
Diagnostic test interference 303
Mechanism 303
Pharmacology/kinetics 303
Pregnancy risk factor 303
Further reading 303
Chapter 205: Sulfadimethoxine 303
Use 303
Contraindications/warnings 304
Dosage 304
Dose adjustments 304
Administration 304
Electrolyte contents 304
Storage/stability 304
Adverse reactions 304
Drug interactions 305
Monitoring 305
Overdose 305
Diagnostic test interference 305
Mechanism 305
Pharmacology/kinetics 305
Pregnancy risk factor 305
References 305
Further reading 306
Chapter 206: Tinidazole 306
Use 306
Contraindications/warnings 306
Dosage 306
Dose adjustments 306
Administration 306
Electrolyte contents 306
Storage/stability 306
Adverse reactions 306
Drug interactions 307
Monitoring 307
Overdose 307
Diagnostic test interference 307
Mechanism 307
Pharmacology/kinetics 307
Pregnancy risk factor 307
References 307
Further reading 307
Section G Antiviral Agents 309
Chapter 207: Acyclovir 309
Use 309
Contraindications/warnings 309
Dosage 309
Dose adjustments 309
Administration 309
Electrolyte contents 309
Storage/stability 309
Adverse reactions 310
Drug interactions 310
Monitoring 310
Overdose 310
Diagnostic test interference 310
Mechanism 310
Pharmacology/kinetics 310
Pregnancy risk factor 310
Further reading 311
Chapter 208: Famciclovir 311
Use 311
Contraindications/warnings 311
Dosage 311
Dose adjustments 311
Administration 311
Electrolyte contents 311
Storage/stability 312
Adverse reactions 312
Drug interactions 312
Monitoring 312
Overdose 312
Diagnostic test interference 312
Mechanism 312
Pharmacology/kinetics 312
Pregnancy risk factor 312
Further reading 313
Chapter 209: Cidofovir 313
Use 313
Contraindications/warnings 313
Dosage 313
Dose adjustments 313
Administration 313
Electrolyte contents 313
Storage/stability 313
Adverse reactions 313
Drug interactions 314
Monitoring 314
Overdose 314
Diagnostic test interference 314
Mechanism 314
Pharmacology/kinetics 314
Pregnancy risk factor 314
Further reading 314
Chapter 210: Idoxuridine 314
Use 315
Contraindications/warnings 315
Dosage 315
Dose adjustments 315
Administration 315
Electrolyte contents 315
Stability/storage 315
Adverse reactions 315
Drug interactions 315
Monitoring 315
Overdose 315
Diagnostic test interference 315
Mechanism 315
Pharmacology/kinetics 315
Pregnancy risk factor 316
Further reading 316
Chapter 211: Oseltamivir 316
Use 316
Contraindications/warnings 316
Dosage 316
Dose adjustments 316
Administration 316
Electrolyte contents 317
Storage/stability 317
Adverse reactions 317
Drug interactions 317
Monitoring 317
Overdose 317
Diagnostic test interference 317
Mechanism 317
Pharmacology/kinetics 317
Pregnancy risk factor 317
Further reading 318
Chapter 212: Vidarabine 318
Use 318
Contraindications/warnings 318
Dosage 318
Dose adjustments 318
Administration 318
Electrolyte contents 318
Storage/stability 318
Adverse reactions 318
Drug interactions 318
Monitoring 318
Overdose 318
Diagnostic test interference 319
Mechanism 319
Pharmacology/kinetics 319
Pregnancy risk factor 319
Further reading 319
Chapter 213: Zidovudine 319
Use 319
Contraindications/warnings 319
Dosage 320
Dose adjustments 320
Administration 320
Electrolyte contents 320
Storage/stability 320
Adverse reactions 320
Drug interactions 320
Monitoring 320
Overdose 320
Diagnostic test interference 320
Mechanism 320
Pharmacology/kinetics 320
Pregnancy risk factor 321
Further reading 321
Index 322
EULA 327

Rezensionen

"Overall, I found this book to be a useful clinical handbook well worth the price. It is recommended as a practical clinical reference for small animal practitioners with limited experience in the area of infectious disease or veterinary students interested in learning clinical information necessary to effectively treat dogs and cats with common infectious diseases." (Journal of the American Veterinary Medical Association, 15 December 2015)
"A very useful tool to enrich whatever formulary may be lying in the consulting room." (Vet Nurses Today, 1 October 2015)

"This book is quite unique in its systematic and logic structure and is a welcome addendum to current literature in this topic." (EJCAP 2016)

"From diagnosis and dosages to risk factors and resources for further reading in professional veterinary publications, all the guidelines and details are written with clinical settings in mind, making this a top office pick." (Midwest Book Review 2016)

Produkt-Details

• Erscheint lt. Verlag: 11.5.2015
• Sprache: englisch
• Themenwelt: Medizin / Pharmazie
• Themenwelt: Veterinärmedizin ► Klinische Fächer
• Themenwelt: Veterinärmedizin ► Kleintier
• Schlagworte: Hundekrankheit • Katzenkrankheit • <p>Infectious disease, pharmacology, antibiotics, antifungals, antiparasitics, antivirals, virus, bacteria, roundworms, pinworms, ticks, mites, fleas, ringworms, tapeworms, dose, dosing, treatment, prescribing, dog, cat, canine, feline, small animal</p> • Pharmakologie • Veterinärmedizin • Veterinärmedizin / Hunde u. Katzen • Veterinärmedizin / Mikrobiologie,Parasitologie,Infektionen,Immunologie • Veterinärmedizin / Pharmakologie, Toxikologie, Therapeutik • Veterinärmedizin • Veterinärmedizin / Hunde u. Katzen • Veterinärmedizin / Mikrobiologie,Parasitologie,Infektionen,Immunologie • Veterinärmedizin / Pharmakologie, Toxikologie, Therapeutik • Veterinary Medicine • Veterinary Medicine - Dogs & Cats • Veterinary Microbiology, Parasitology,Infectious Diseases & Immunology • Veterinary Pharmacology, Toxicology & Therapeutics
• ISBN-13: 9781118557471 / 9781118557471